FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362488008> ?p ?o ?g. }

• W4362488008 abstract "<div>Abstract<p>MRP-1 is implicated in multidrug resistance and was described as prognostic in high-risk patients with soft-tissue sarcoma (STS) in a previous study. The current research aimed to validate MRP-1 prognostic/predictive value in localized sarcomas treated with anthracyclines plus ifosfamide within the ISG-1001 phase III study. In addition, the inhibitory activity on MRP-1 was investigated in preclinical studies to identify new combinations able to increase the efficacy of standard chemotherapy in STS. MRP-1 expression was assessed by IHC in tissue microarrays from patients with STS and tested for correlation with disease-free survival (DFS) and overall survival (OS). <i>In vitro</i> studies tested the efficacy of MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, and avapritinib) in sarcoma cell lines. The effect of combinations of the most active MRP-1 inhibitors and chemotherapy was measured on the basis of apoptosis. MRP-1 was evaluable in 231 of 264 cases who entered the study. MRP-1 expression (strong intensity) was independently associated with worse DFS [HR, 1.78; 95% confidence interval (CI), 1.11–2.83; <i>P</i> = 0.016], in the multivariate analysis, with a trend for a worse OS (HR, 1.78; 95% CI, 0.97–3.25; <i>P</i> = 0.062). <i>In vitro</i> studies showed that the addition of MRP-1 inhibitors (nilotinib or avapritinib) to doxorubicin plus palifosfamide, significantly increased cell death in SK-UT-1 and CP0024 cell lines. MRP-1 is an adverse predictive factor in localized high-risk patients with STS treated with neoadjuvant anthracyclines plus ifosfamide followed by surgery. <i>In vitro</i> findings support the clinical assessment of the combination of chemotherapy and MRP-1 inhibitors as a promising strategy to overcome the drug ceiling effect for chemotherapy.</p></div>" @default.
• W4362488008 created "2023-04-05" @default.
• W4362488008 creator A5006074198 @default.
• W4362488008 creator A5007668813 @default.
• W4362488008 creator A5008115301 @default.
• W4362488008 creator A5009531132 @default.
• W4362488008 creator A5009957675 @default.
• W4362488008 creator A5013226419 @default.
• W4362488008 creator A5020137513 @default.
• W4362488008 creator A5023576532 @default.
• W4362488008 creator A5024463077 @default.
• W4362488008 creator A5028257477 @default.
• W4362488008 creator A5034220270 @default.
• W4362488008 creator A5040210154 @default.
• W4362488008 creator A5042202815 @default.
• W4362488008 creator A5045537084 @default.
• W4362488008 creator A5046159238 @default.
• W4362488008 creator A5050031420 @default.
• W4362488008 creator A5059311375 @default.
• W4362488008 creator A5060954086 @default.
• W4362488008 creator A5060977707 @default.
• W4362488008 creator A5061442888 @default.
• W4362488008 creator A5061469135 @default.
• W4362488008 creator A5066380305 @default.
• W4362488008 creator A5067480587 @default.
• W4362488008 creator A5067601660 @default.
• W4362488008 creator A5073627444 @default.
• W4362488008 creator A5079825894 @default.
• W4362488008 creator A5080548972 @default.
• W4362488008 creator A5082472276 @default.
• W4362488008 creator A5083948167 @default.
• W4362488008 creator A5085410610 @default.
• W4362488008 date "2023-04-03" @default.
• W4362488008 modified "2023-10-18" @default.
• W4362488008 title "Data from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial" @default.
• W4362488008 doi "https://doi.org/10.1158/1535-7163.c.6543519" @default.
• W4362488008 hasPublicationYear "2023" @default.
• W4362488008 type Work @default.
• W4362488008 citedByCount "0" @default.
• W4362488008 crossrefType "posted-content" @default.
• W4362488008 hasAuthorship W4362488008A5006074198 @default.
• W4362488008 hasAuthorship W4362488008A5007668813 @default.
• W4362488008 hasAuthorship W4362488008A5008115301 @default.
• W4362488008 hasAuthorship W4362488008A5009531132 @default.
• W4362488008 hasAuthorship W4362488008A5009957675 @default.
• W4362488008 hasAuthorship W4362488008A5013226419 @default.
• W4362488008 hasAuthorship W4362488008A5020137513 @default.
• W4362488008 hasAuthorship W4362488008A5023576532 @default.
• W4362488008 hasAuthorship W4362488008A5024463077 @default.
• W4362488008 hasAuthorship W4362488008A5028257477 @default.
• W4362488008 hasAuthorship W4362488008A5034220270 @default.
• W4362488008 hasAuthorship W4362488008A5040210154 @default.
• W4362488008 hasAuthorship W4362488008A5042202815 @default.
• W4362488008 hasAuthorship W4362488008A5045537084 @default.
• W4362488008 hasAuthorship W4362488008A5046159238 @default.
• W4362488008 hasAuthorship W4362488008A5050031420 @default.
• W4362488008 hasAuthorship W4362488008A5059311375 @default.
• W4362488008 hasAuthorship W4362488008A5060954086 @default.
• W4362488008 hasAuthorship W4362488008A5060977707 @default.
• W4362488008 hasAuthorship W4362488008A5061442888 @default.
• W4362488008 hasAuthorship W4362488008A5061469135 @default.
• W4362488008 hasAuthorship W4362488008A5066380305 @default.
• W4362488008 hasAuthorship W4362488008A5067480587 @default.
• W4362488008 hasAuthorship W4362488008A5067601660 @default.
• W4362488008 hasAuthorship W4362488008A5073627444 @default.
• W4362488008 hasAuthorship W4362488008A5079825894 @default.
• W4362488008 hasAuthorship W4362488008A5080548972 @default.
• W4362488008 hasAuthorship W4362488008A5082472276 @default.
• W4362488008 hasAuthorship W4362488008A5083948167 @default.
• W4362488008 hasAuthorship W4362488008A5085410610 @default.
• W4362488008 hasConcept C126322002 @default.
• W4362488008 hasConcept C142724271 @default.
• W4362488008 hasConcept C143998085 @default.
• W4362488008 hasConcept C170493617 @default.
• W4362488008 hasConcept C193270364 @default.
• W4362488008 hasConcept C204232928 @default.
• W4362488008 hasConcept C2776694085 @default.
• W4362488008 hasConcept C2777413986 @default.
• W4362488008 hasConcept C2777506904 @default.
• W4362488008 hasConcept C2778119113 @default.
• W4362488008 hasConcept C2778256501 @default.
• W4362488008 hasConcept C2778629024 @default.
• W4362488008 hasConcept C2781303535 @default.
• W4362488008 hasConcept C42362537 @default.
• W4362488008 hasConcept C502942594 @default.
• W4362488008 hasConcept C71924100 @default.
• W4362488008 hasConceptScore W4362488008C126322002 @default.
• W4362488008 hasConceptScore W4362488008C142724271 @default.
• W4362488008 hasConceptScore W4362488008C143998085 @default.
• W4362488008 hasConceptScore W4362488008C170493617 @default.
• W4362488008 hasConceptScore W4362488008C193270364 @default.
• W4362488008 hasConceptScore W4362488008C204232928 @default.
• W4362488008 hasConceptScore W4362488008C2776694085 @default.
• W4362488008 hasConceptScore W4362488008C2777413986 @default.
• W4362488008 hasConceptScore W4362488008C2777506904 @default.
• W4362488008 hasConceptScore W4362488008C2778119113 @default.
• W4362488008 hasConceptScore W4362488008C2778256501 @default.
• W4362488008 hasConceptScore W4362488008C2778629024 @default.
• W4362488008 hasConceptScore W4362488008C2781303535 @default.
• W4362488008 hasConceptScore W4362488008C42362537 @default.

• next